Login to Your Account

Emerging Markets

'No Exit' on Chinese Markets Despite Relaxing of IPO Ban

By Shannon Ellis
Contributing Writer

Wednesday, June 26, 2013

SHANGHAI, China – Chinese biopharmaceutical companies are unlikely to benefit much from a relaxation in an 8-month-old ban on new initial public offerings (IPOs) or from new draft regulations aimed at improving disclosures and governance.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription